Replies to post #286627 on Avid Bioservices Inc (CDMO)

[Protector]

cjgaddy, I think your search here is quite conclusive, THANKS!

“. . .The method may further comprise diagnosing the subject from which the sample was obtained as having cancer. The method may further comprise staging the cancer or classifying the cancer type in the subject from which the sample was obtained. The method may further comprise performing steps (a)-(c) a 2nd time, and comparing the results from the 1st & 2nd times, thereby assessing cancer progression or regression. The method may further comprise performing steps (a)-(c) a 2nd time, wherein the subject has received a cancer therapy after the 1st performance of steps (a)-(c) and before the 2nd performance of steps (a)-(c), and comparing the results from the 1st & 2nd times, thereby assessing the efficacy of cancer therapy. The method may further comprise treating the subject with a cancer therapy. . .
In addition to PS, exosomes exhibit a number of unique & non-unique markers. Some of the exosome-specific markers include biomarkers that can help distinguish the nature of the type of cancer from which the exosome originated. Some exemplary exosome biomarkers can be found above in Table 1. Global exosome biomarkers that can be detected with appropriately labeled agents include cd9, cd63, cd81, ALIX, HSP70, TSG101, duramycin, and heparin.”

So this test can detect the following:

A) HAS CANCER (BINARY YES or NO, incl. pro-active use)
B) STAGING
C) CLASSIFYING THE TYPE OF CANCER (
D) ASSESSING CANCER PROGRESSION or REGRESSION
E) ASSESSING THE EFFICACY OF CANCER THERAPY

That is IMPRESSIVE, that ranges from taking this test PROACTIVELY, over as part of a DIAGNOSTIC into MONITORING and FOLLOW-UP.

For most patients this is not just one single test. This is a series of pro-active tests and/or several tests when you would have contracted a cancer.

This is just HUGE even for BP.